Expert Opinion Grade E Based on the inclusion criteria used in the RCTs reviewed by the panel, this recommendation applies to individuals younger than 70 years with an estimated GFR or measured GFR less than and in people of any age with albuminuria defined as greater than 30 mg of albumin/g of creatinine at any level of GFR. question 2. In adults younger than 70 years with CKD, the evidence is insufficient to determine if there is a benefit in mortality, or car- diovascularorcerebrovascularhealthoutcomeswithantihyperten- dence statement 15). There is evidence of moderate quality dem- onstrating no benefit in slowing the progression of kidney disease from treatment with antihypertensive drug therapy to a lower BP goal (for example, <130/80 mm Hg) compared with a goal of lower than 140/90 mm Hg (question 2, evidence statement 16). Three trials that met our criteria for review addressed the effect of antihypertensive drug therapy on change in GFR or time to development of ESRD, but only one trial addressed cardiovas- cular disease end points. Blood pressure goals differed across the trials, with 2 trials (AASK and MDRD) using mean arterial pressure and different targets by age, and 1 trial (REIN-2) using only DBP None of the trials showed that treatment to a lower BP goal (for example, <130/80 mm Hg) significantly lowered kidney or cardiovascular disease end points compared with a goal of lower than 140/90 mm Hg. 